Home / Industry News / 2010 / Forbes India: How the Abbott-Piramal Deal Went Down

Forbes India: How the Abbott-Piramal Deal Went Down

Source: PharmaManufacturing.com

Jun 08, 2010

business.in.com

Print Email

Show More Content

More News:

Amarin defies critics with more positive Vascepa data

03/18/2019

Amarin Corp. has released new data from a study showing that its fish oil medication, Vascepa, can significantly reduce the occurrence of several adverse heart events.
Novartis' Alcon buys PowerVision

03/18/2019

Alcon, Novartis' eye care division, has acquired PowerVision, a privately-held medical device development company focused on creating fluid-based intraocular lens implants.
Prosecutors raid Korean Exchange in Samsung Bio probe

03/15/2019

Samsung Biologics is again in the spotlight over its 2016 initial public offering as prosecutors raided the office of the Korea Exchange.
Novartis Sandoz CEO steps down

03/15/2019

Novartis has announced that Richard Francis will be stepping down as CEO of Sandoz.
Drugmakers join Fox News show boycotts

03/15/2019

Several drugmakers are joining the growing group of protestors who are distancing themselves from the Fox News Channel shows featuring Tucker Carlson and Jeanine Pirro after the hosts were accused of making bigoted statements.
FDA warns Jubilant India plant

03/14/2019

The U.S. FDA has issued a warning letter to Jubilant Generics for its Roorkee, North India facility.
FDA combats valsartan shortage with new generic approval

03/14/2019

As recalls widen for the popular blood pressure medication, valsartan, the FDA has approved a new generic version of the drug.
J&J labeled the ‘kingpin’ of the opioid epidemic in Ok. lawsuit

03/14/2019

As litigation against manufacturers involved in opioid sales continues to mount, lawyers in an Oklahoma lawsuit have taken aim at Johnson & Johnson.
National Cancer Institute head to act as FDA commissioner

03/12/2019

While the search for a permanent FDA chief is still ongoing, Norman Sharpless will take over Scott Gottlieb's position in April.
Fujifilm buys Biogen biologics unit for $890 million

03/12/2019

According to the Japanese company the acquisition is meant to shore up its healthcare business

Pharma Manufacturing

Join the discussion

Comments

J&J labeled the ‘kingpin’ of the opioid epidemic in Ok. lawsuit

As litigation against manufacturers involved in opioid sales continues to…

Drugmakers join Fox News show boycotts

Several drugmakers are joining the growing group of protestors who are…

Roche grabs first breast cancer immunotherapy approval

Roche’s Tecentriq is now the first immunotherapy drug approved by the…

Martin Shkreli investigated for running pharma company from jail

The infamous “Pharma Bro” is in the hot seat again — this time for…

FDA warns Jubilant India plant

The U.S. FDA has issued a warning letter to Jubilant Generics for its…

FDA hands Akorn its fourth 483

The FDA has issued Akorn a Form 483, following an inspection of the…

The FDA finds a third cancer-causing toxin in recalled blood pressure meds

A global recall of a commonly used blood pressure medication has widened…

After two deaths, FDA hits the brakes on leukemia treatment study

The FDA has placed a partial hold on a phase 1 study into the study of a…

J&J labeled the ‘kingpin’ of the opioid epidemic in Ok. lawsuit

As litigation against manufacturers involved in opioid sales continues to…

Cohen: Novartis wanted access to the president

In a bombshell testimony before Congress, President Trump’s ex-lawyer…

Top Pharma Manufacturing Predictions for 2019

From new tech to innovative business models and shifting regulations,…

Top 5 Drugs With the Biggest Growth Potential in 2019

In the coming year, several drugs that treat a range of diseases will far…

Boehringer cuts nearly 300 jobs in France

The company's French workforce will see 327 jobs cut but will also see 32…

FDA slaps Akorn plant with Form 483

The regulatory body found issues at the drugmaker's New Jersey site,…

Roche R&D exec leaves pharma for biotech, joins Voyager Therapeutics

Voyager Therapeutics appoints Omar Khwaja as its chief medical officer,…

Weighing and Dispensing: Do it Right

The weighroom is the entry point to manufacturing and a transition point…

Annual Product Reviews: How to Conduct an Effective Annual Product Quality Review

More than just a regulatory requirement, an APR helps the manufacturer to…

CAPA and Root Cause Analysis

Recent FDA Warning Letters have cited insufficient corrective and…

USP Updates <61> and <62> for Microbial Testing of Non-Steriles

Significant changes include more clarity on enumberation and specified…

Serialization and the Drug Quality & Security Act

The supply chain for genuine pharmaceuticals has grown longer, and every…